Latest & greatest articles for lisdexamfetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lisdexamfetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lisdexamfetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lisdexamfetamine

1. Lisdexamfetamine

Lisdexamfetamine Top results for lisdexamfetamine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lisdexamfetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (PubMed)

Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine (...) dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition.Twenty-five adults with ADHD were scanned twice with event-related functional magnetic resonance imaging while performing an emotional go/no-go task after 3 to 4 weeks of lisdexamfetamine treatment and 3 weeks off medication in a randomized, counterbalanced, hybrid crossover design. Drug, trial type, and face emotion (happy, sad, or neutral) were included as within-subjects factors

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging

3. Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final Appraisal Recommendation Advice No: 2615 – September 2015 Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules Submission by Shire Pharmaceuticals Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2534 (...) the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2615: Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules. September 2015. Recommendation of AWMSG Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

2015 All Wales Medicines Strategy Group

4. Lisdexamfetamine dimesylate (Elvanse Adult®)

Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Lisdexamfetamine dimesylate (Elvanse Adult®) Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2534. 2015 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Attention Deficit Disorder with Hyperactivity

2015 Health Technology Assessment (HTA) Database.

5. Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment) Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V. [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 186. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder

2014 Health Technology Assessment (HTA) Database.

6. lisdexamfetamine dimesylate (Elvanse®)

lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). lisdexamfetamine dimesylate (Elvanse®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 188. 2013 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision

2014 Health Technology Assessment (HTA) Database.

7. Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD)

Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - lisdexamfetamine dimesylate (Elvanse) | | Appraisal information Search and reports lisdexamfetamine dimesylate (Elvanse®) Reference No. 188 Publication date: 03/12/2013 Last review date: 01/12/2016 Appraisal information lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule lisdexamfetamine dimesylate (Elvanse® (...) ) 70 mg capsule Company: Shire Pharmaceuticals Ltd BNF category: Central nervous system NMG meeting date: 11/09/2013 AWMSG meeting date: 16/10/2013 Submission Type: Full Submission Status: Recommended Advice No: 2813 Ratification by Welsh Government: 02/12/2013 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment

2013 All Wales Medicines Strategy Group

8. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate Attention deficit h Attention deficit hyper yperactivity disorder in activity disorder in children and y children and young people: lisde oung people: lisdexamfetamine xamfetamine dimesylate dimesylate Evidence summary Published: 7 May 2013 nice.org.uk/guidance/esnm19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May (...) 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Limited evidence from 1 RCT suggests that lisdexamfetamine dimesylate produces clinically meaningful benefits in ADHD symptoms compared with placebo. The adverse effect profile appears similar to other stimulant drugs, although theoretical advantages in terms of improved adherence and reduced abuse potential require further

2013 National Institute for Health and Clinical Excellence - Advice

9. Lisdexamfetamine dimesylate - Benefit assessment according to § 35a Social Code Book V

Lisdexamfetamine dimesylate - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment “Lisdexamfetamindimesilat – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 29 August 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A13-24 Lisdexamfetamine (...) dimesylate – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A13-24 Version 1.0 Lisdexamfetamine dimesylate – Benefit assessment acc. to § 35a SGB V 29 August 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lisdexamfetamine dimesylate – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Treating Children Age 6-12 with Attention Deficit Hyperactivity Disorder

Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Treating Children Age 6-12 with Attention Deficit Hyperactivity Disorder "Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetami" by McKenzie Thurman < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette (...) Sommers MS, PA-C Rights . Abstract Background: Lisdexamfetamine Dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. Pharmacologically active d-amphetamine is released from Lisdexamfetamine following oral ingestion. It is indicated in the treatment of children ages 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The goal of LDX is to provide a one dose, extended release medication throughout the day as well as a reduced potential for abuse, overdose toxicity and drug misuse

2009 Pacific University EBM Capstone Project